Visit esporist.com for more information.
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
· Financial Post
PARIS, FRANCE, 16 May 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant neuroinhibitor, RNITM. Built from engineered functional domains of A (catalytic) and B (binding), every element of its structure has been deliberately optimized to increase receptor affinity, enhance uptake, and improve resistance to degradation. Read More